Outlook Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Dec 19, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Dec 19, 2025

OTLK$0.46+5.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year ended September 30,
· · 2025 · · 2024
Revenues, net	$1,413,535	$—
Cost of revenues	1,356,330	—
Gross profit	57,205	—
Operating expenses:
Research and development	27,180,640	41,763,047
Selling, general and administrative	39,938,231	29,940,188
Loss from operations	(67,061,666)	(71,703,235)
Loss on equity method investment	141,007	100,742
Interest income	(89,738)	(906,150)
Interest expense	283,128	3,156,964
Loss from change in fair value of promissory notes	6,074,586	2,457,153
Warrant related expenses (Note 10)	—	37,490,012
Warrant inducement expenses (Note 10)	33,521,874	—
Gain from change in fair value of warrant liability	(43,015,831)	(38,638,042)
Loss before income taxes	(63,976,692)	(75,363,914)
Income tax (benefit) expense	(1,551,829)	2,800
Net loss	$(62,424,863)	$(75,366,714)

Per share information:
Net loss per share of common stock, basic and diluted	$(1.79)	$(4.06)
Weighted average shares outstanding, basic and diluted	34,796,120	18,548,813

See accompanying notes to consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.